| 2 | 3 | | |
|---|
| 3 | 4 | | |
|---|
| 4 | 5 | | |
|---|
| 5 | 6 | | |
|---|
| 6 | 7 | | R E S O L U T I O N |
|---|
| 7 | 8 | | WHEREAS, Dr. Jennifer Keating Litton of The University of |
|---|
| 8 | 9 | | Texas MD Anderson Cancer Center in Houston has distinguished |
|---|
| 9 | 10 | | herself through her many contributions to cancer research and |
|---|
| 10 | 11 | | treatment; and |
|---|
| 11 | 12 | | WHEREAS, Over the course of her tenure at MD Anderson, Dr. |
|---|
| 12 | 13 | | Litton has held numerous leadership positions, including chief of |
|---|
| 13 | 14 | | the Section of Clinical Research and Drug Development in the |
|---|
| 14 | 15 | | Department of Breast Medical Oncology, where she also served as an |
|---|
| 15 | 16 | | associate professor; she has also spearheaded the Breast Medical |
|---|
| 16 | 17 | | Oncology Education Program, the Scientific Review Research |
|---|
| 17 | 18 | | Committee, and the Genitourinary Chair Search Committee; she |
|---|
| 18 | 19 | | currently serves as vice president of clinical research, leading |
|---|
| 19 | 20 | | the largest cancer clinical trials program in the country with more |
|---|
| 20 | 21 | | than 1,500 clinical trials and over 10,000 patients enrolled in |
|---|
| 21 | 22 | | therapeutic trials; moreover, she is a member of the faculty at the |
|---|
| 22 | 23 | | UTHealth Houston Graduate School of Biomedical Sciences at MD |
|---|
| 23 | 24 | | Anderson; and |
|---|
| 24 | 25 | | WHEREAS, Dr. Litton has been involved in numerous committees |
|---|
| 25 | 26 | | and organizations, including the Society for Immunotherapy of |
|---|
| 26 | 27 | | Cancer, the American Society of Clinical Oncology, the Society of |
|---|
| 27 | 28 | | Surgical Oncology, the American Society for Radiation Oncology, the |
|---|
| 28 | 29 | | FORCE Advisory Board, the Clinical Cancer Genetics Steering |
|---|
| 29 | 30 | | Committee, and Living Beyond Breast Cancer; she is also a member of |
|---|
| 30 | 31 | | Suites of Hope in Houston and the Texas Lyceum in Austin; in 2018, |
|---|
| 31 | 32 | | she received the President's Recognition of Faculty Excellence |
|---|
| 32 | 33 | | Award in Prevention Outreach from MD Anderson; and |
|---|
| 33 | 34 | | WHEREAS, Board certified in oncology and internal medicine, |
|---|
| 34 | 35 | | Dr. Litton focuses her research on pregnancy and breast cancer, |
|---|
| 35 | 36 | | genetic testing, and molecular changes of breast cancer genes; she |
|---|
| 36 | 37 | | holds a bachelor's degree from Duke University, a doctor of |
|---|
| 37 | 38 | | medicine degree from the University of Massachusetts Medical |
|---|
| 38 | 39 | | School, and a master's degree in health care management from the |
|---|
| 39 | 40 | | Harvard T. H. Chan School of Public Health; she completed her |
|---|
| 40 | 41 | | residency and chief residency at the Baylor College of Medicine as |
|---|
| 41 | 42 | | well as a fellowship in medical oncology at MD Anderson; and |
|---|
| 42 | 43 | | WHEREAS, Through her leadership, skill, and commitment to |
|---|
| 43 | 44 | | excellence, Dr. Litton has made a lasting and positive impact in her |
|---|
| 44 | 45 | | field, and it is a privilege to join in recognizing this outstanding |
|---|
| 45 | 46 | | professional; now, therefore, be it |
|---|
| 46 | 47 | | RESOLVED, That the House of Representatives of the 89th Texas |
|---|
| 47 | 48 | | Legislature hereby honor Dr. Jennifer Keating Litton for her many |
|---|
| 48 | 49 | | professional achievements and extend to her sincere best wishes for |
|---|
| 49 | 50 | | continued success; and, be it further |
|---|
| 50 | 51 | | RESOLVED, That an official copy of this resolution be |
|---|
| 51 | 52 | | prepared for Dr. Litton as an expression of high regard by the Texas |
|---|
| 52 | 53 | | House of Representatives. |
|---|